CURIS INC

Rubin Marc’s latest option buy in Curis Inc. signals strong confidence in upcoming Phase III results for Cure‑X, a safety‑validated cell‑therapy poised for PMA.

Curis insider buys 100‑share Series B preferred & 133k warrants—management bets on a Phase 2 milestone, hinting at a potential price rally amid $0.89 volatility.